Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for
chronic weight management provides a novel effective strategy against obesity. The reliable …

Study objective Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist used
for management of type 2 diabetes and/or obesity. To test the hypothesis that perioperative …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …

GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …

Obesity is a chronic illness associated with several metabolic derangements and
comorbidities (ie, insulin resistance, leptin resistance, diabetes, etc.) and often leads to …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and
obesity for their high efficacy in controlling glycaemia and inducing body weight loss …

Gastric emptying is a major determinant of postprandial blood glucose, accounting for~ 35%
of variance in peak glucose in both healthy individuals and those with type 2 diabetes …